1. Introduction {#s0005}
===============

Leber hereditary optic neuropathy (LHON, OMIM\#535000) is a common cause of inherited blindness that typically presents with bilateral, painless, sub-acute visual failure in young adult males ([@bb0030]). The diagnosis is usually confirmed by molecular genetic analysis for one of three common mitochondrial DNA (mtDNA) mutations which all affect genes coding for complex I subunits of the respiratory chain: m.3460 G \> A, m.11778 G \> A and m14484T \> C. However, not all patients harbouring a pathogenic LHON mtDNA mutation develop visual failure ([@bb0015]). Segregation analysis of LHON pedigrees implicates a two-locus model, with the mtDNA mutation as one locus and a modulating nuclear chromosomal locus ([@bb0020]). However, attempts to identify a nuclear modifying gene by both genetic mapping and functional genomics have been inconclusive ([@bb0035; @bb0065; @bb0075]).

Affected individuals develop focal degeneration of the optic nerve and present clinically with impaired color vision (dyschromatopsia), a dense visual field defect (central or caecocentral scotoma) and abnormal visual electrophysiology due to primary retinal ganglion cell loss (RGC) ([@bb0030]). Although the primary biochemical defect involves complex I of the mitochondrial respiratory chain, the mechanisms leading to neurodegeneration remain unclear. Optical coherence tomography has shown an initial thickening of the retinal nerve fibre layer before the onset of visual symptoms, followed by progressive thinning corresponding to the axonal loss ([@bb0010]). Recently, phosphorylated neuronal filament heavy chain (pNF-H), a prospective marker for neurodegeneration in Alzheimer\'s disease ([@bb0090; @bb0095]), was shown to be elevated in the serum of LHON patients ([@bb0060]).

Phosphorylation of the tau protein, encoded by the *MAPT* gene on chromosome 17, has been shown to result in neurodegeneration through the accumulation of neurofilamentray tangles (NFT). Variation in *MAPT* has been associated with a range of neurodegenerative disorders, providing evidence that disrupting tau homeostasis is sufficient to cause neuronal degeneration ([@bb0025; @bb0040; @bb0100]), with particular variants tagging to two distinct disease related sub-haplotypes (H1 and H2) ([@bb0005]). Of particular interest, both *MAPT* variation and a biochemical defect of complex I also appear to be involved in the pathogenesis of Parkinson\'s disease.

Given the emerging evidence that tau-mediated neurodegeneration is caused by a combination of factors, including mitochondrial dysfunction ([@bb0120]), it is plausible that *MAPT* variation contributes to the risk of blindness in LHON mtDNA mutation carriers.

2. Materials and methods {#s0010}
========================

We studied 10 common *MAPT* (NM_001123066.3) single nucleotide polymorphisms (SNPs): (rs9486, rs242562, rs2435205, rs2435207, rs1467966, rs1800547, rs242557, rs2435211, rs2471738, rs3785883) in a European cohort consisting of 288 patients with LHON and 336 unaffected LHON family members (from 214 unrelated families) all harbouring a homoplasmic primary LHON mtDNA mutation. The clinical phenotype was determined by a local ophthalmologist, and all subjects were homoplasmic for one of the primary LHON mtDNA mutations (patients --- m.3460G\>A, n = 51, m.11778G\>A, n = 201, m.14484T\>C, n = 23, m.14495G\>A, n = 1, and unaffected family members --- m.3460G\>A, n = 71, m.11778G\>A, n = 226, m.14484T\>C, n = 18, m.14495G\>A, n = 0, 15257 = 21). Mutation status was confirmed by direct sequencing of the *MTND* genes or PCR-RFLP analysis as previously described ([@bb0115]). Unaffected carriers were classified and included only if they had remained asymptomatic until \> 30 years of age.

SNPs were selected using the following criteria: (1) substitutions predicted to affect *MAPT* function or shown to increase the risk of Parkinson\'s disease ([@bb0055; @bb0110; @bb0125; @bb0130]); (2) presence in control subjects at \> 1.0% (dbSNP) ([@bb0105]). *MAPT* H1 and H2 sub typing were performed by rs9486 allelic discrimination ([@bb0055; @bb0110]).

The frequency of sequence variants was determined by primer extension of multiplex polymerase chain reaction products with the detection of the allele-specific extension products by matrix-associated laser desorption/ionization time of flight (MALDITOF; Sequenom, San Diego, CA) mass spectrometry.

Allele and genotype frequencies were compared using uncorrected Fishers exact test. Multiple logistic regression was performed to look for interactions between the variables. Age of onset was assessed as survivability using Kaplan--Meier, with comparisons made via Mantel--Cox log rank test. All analyses were carried out using SPSS software version 17.0 (SPSS Inc.). Statistical power was calculated using power for association with error (PAWE) ([@bb0050]).

3. Results {#s0015}
==========

3.1. MAPT haplotyping {#s0020}
---------------------

The distribution of *MAPT* H1/H2 haplotypes and genotypes in both affected LHON cases and unaffected LHON mtDNA mutation carriers was not significantly different to published population controls ([@bb0110]) (affected LHON cases versus published controls P = 0.613 and unaffected LHON mtDNA mutation carriers versus published controls P = 0.727, [Table 1](#t0005){ref-type="table"}). There was no significant difference in the frequency of *MAPT* H1/H2 haplotypes (P = 0.656) or H1/H2 alleles (P = 0.638, [Table 1](#t0005){ref-type="table"}) when affected LHON cases were compared to unaffected LHON mtDNA mutation carriers. Given the male predominance of affected LHON cases, we compared H- genotype and allele frequencies in males and females separately, but again were unable to find a significant association (Genotype; males P = 0.573 and females P = 0.626 alleles; males P = 0.455 and females P = 0.797).

3.2. Variant genotyping {#s0025}
-----------------------

There was no significant association between; rs242562, rs2435205, rs2435207, rs1467966, rs1800547, rs242557, rs2435211, rs2471738 or rs3785883 and visual failure in the European LHON mutation carriers when comparing alleles or genotypes ([Table 2](#t0010){ref-type="table"}). Again, given the male bias in LHON, we compared the frequency of the *MAPT* variants in both males and females separately, but were unable to identify a significant association.

3.3. Effect of mitochondrial DNA background {#s0030}
-------------------------------------------

The clinical penetrance of LHON is strongly associated with mtDNA haplogroup J ([@bb0080]). With this is mind, we compared MAPT H-haplotypes and the common *MAPT* variants in both J and non-J haplogroups by logistic regression analysis, controlling for gender. This failed to identify an interacting association between background mitochondrial haplogroup J and H1, H2 and H1:H2 haplotypes and the presence of visual failure in LHON mtDNA mutation carriers (P value for H1 haplotype = 0.749, H2 haplotype = 0.190 and H1/H2 haplotypes = 0.553).

Similarly, we found no association between visual failure, the common *MAPT* variants and haplogroup J by logistic regression, again controlling for gender, (P = rs242562 = 0.749, rs2435205 = 0.357, rs2435207 = 0.731, rs1467966 = 0.760, rs1800547 = 0.594, rs242557 = 0.203, rs2435211 = 0.409, rs2471738 = 0.659 or rs3785883 = 0.665). There was no significant association identified with H-haplotypes (P value for H1 haplotype = 0.357, H2 haplotype = 0.151 and H1/H2 haplotypes = 0.909), or common MAPT variants when limiting to non-J haplogroups.

3.4. Age of onset {#s0035}
-----------------

To assess the potential effect of H-haplotype and genotype on the age of onset of visual symptoms we compared H1 and H2 alleles to the age of onset of 250 symptomatic LHON patients (mean age of onset 22.60 years, StDev = 14.30). We were unable to identify a significant difference between H1 and H2 carriers (Mantel--Cox P = 0.623), further analysis showed no significant difference in age of onset when comparing *MAPT* common variants and age of onset (Mantel--Cox P = rs242562 = 0.762, rs2435205 = 0.621, rs2435207 = 0.346, rs1467966 = 0.289, rs1800547 = 0.416, rs242557 = 0.516, rs2435211 = 0.723, rs2471738 = 0.654 and rs3785883 = 0.251).

4. Discussion {#s0040}
=============

We conducted a large case control study of *MAPT* variants previously shown to be associated with neurodegenerative disorders ([@bb0055; @bb0110; @bb0125; @bb0130]); based on the hypothesis that common variation in the *MAPT* gene is a major factor responsible for the incomplete penetrance in LHON. Previous studies have shown that the H1 haplotype is over represented in tauopathies ([@bb0055; @bb0110; @bb0125; @bb0130]), demonstrating increased risk to neurodegeneration, and the H2 haplotype has been shown to alter neuronal glucose utilisation ([@bb0085]), a factor known to be important in LHON ([@bb0045; @bb0070]). However, we found no significant association to H-haplotypes and the presence or age of onset of the visual failure.

Previous studies have identified significant association to a number of *MAPT* SNPs, particularly rs1800547, rs2471738 and rs242557 ([@bb0125; @bb0130]), to neurodegenerative disorders. We were unable to replicate these findings in LHON. Given an affected population size of 288 and a control population size of 336 our power to detect a \> 10% difference in cases/control allele frequency was 0.942, and a 10% difference in genotype frequency was 0.893. With a 5% genotyping error (∑ 1 = Pr = 0.05), we would still be expected to detect a \> 10% difference with an allelic power of 0.888 and a genotypic power of 0.817. We therefore conclude that it is highly unlikely that common *MAPT* variants play a major role in determining the variable clinical phenotype in LHON families. It is conceivable that *MAPT* variation plays a minor role, perhaps in combination with other genetic and environmental factors, but this will be extremely difficult to demonstrate given that LHON is a relatively rare disorder affecting \~ 1 in 14,000 males. Collecting a large enough cohort to show more subtle genetic effects would be a major challenge.
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###### 

Comparison of H1/H2 haplogroups in LHON cases, LHON controls and published population controls ([@bb0110]) (shown as frequency and percentage frequency in brackets, where A is symptomatic LHON mtDNA mutation carrier, U is asymptomatic LHON mtDNA mutation carrier and C\* is published population controls. Probability is shown, P, by Fishers Exact test).

        Haplotype                              
  ----- ------------ ------------ ------------ -------
  A     178 (63.1)   19 (6.7)     85 (30.1)    0.656
  U     197 (60.8)   28 (8.6)     99 (30.6)    
  C\*   262 (63.9)   16 (3.6)     143 (32.4)   
        H1           H2                        
  A     263 (71.7)   104 (28.3)                0.638
  U     296 (80.7)   127 (34.6)                

###### 

Allele (A) and genotype (G) comparison of common disease-associated *MAPT* variants in LHON mtDNA mutation carriers (where A is symptomatic LHON and U is asymptomatic mtDNA mutation carrier, P = uncorrected probability by Fishers Exact test).

                    A1    A2      P       G1    G2      G3      P
  ----------- ----- ----- ------- ------- ----- ------- ------- ---
  rs242562          G     A               G     A       GA      
  A           201   182   0.621   76      57    125     0.522   
  U           222   217           84      79    138             
  rs2435205         A     G       0.498   A     G       AG      
  A           218   195   73      50      145   0.392           
  U           232   229   72      69      160                   
  rs2435207         G     A       0.808   G     A       GA      
  A           247   99    173     25      74    0.777           
  U           276   116   194     34      82                    
  rs1467966         T     C       1.000   T     C       TC      
  A           227   113   123     9       104   0.705           
  U           268   135   148     15      120                   
  rs1800547         A     G       0.938   A     G       AG      
  A           224   113   120     9       104   0.799           
  U           262   134   142     14      120                   
  rs242557          G     A       0.605   G     A       GA      
  A           215   132   102     19      113   0.584           
  U           259   173   111     25      148                   
  rs2435211         T     C       1.000   T     C       TC      
  A           224   115   120     11      104   0.546           
  U           224   115   153     17      113                   
  rs2471738         T     C       0.519   T     C       TC      
  A           249   73    179     3       70    0.698           
  U           296   77    222     3       74                    
  rs3785883         G     A       0.919   G     A       GA      
  A           221   57    173     9       48    0.692           
  U           255   66    196     7       59                    
